Oncology and Hematology - Global Oncology Academy

Episodes 225-240 of 397

The Impact of Advocacy on Healthcare
The Impact of Advocacy on Healthcare
Project Oncology®
The Impact of Advocacy on Healthcare
- Ashley L. Sumrall, MD
The Power of Patient Advocacy in Daily Clinical Practice
The Power of Patient Advocacy in Daily Clinical Practice
Project Oncology®
The Power of Patient Advocacy in Daily Clinical Practice
- Ashley L. Sumrall, MD
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
Project Oncology®
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
Real-World Data on Treatment Choices for mccRCC
Real-World Data on Treatment Choices for mccRCC
Project Oncology®
Real-World Data on Treatment Choices for mccRCC
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Project Oncology®
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Project Oncology®
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Project Oncology®
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology®
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
- Alan Bryce, MD
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
DermConsult
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
Project Oncology®
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
- Charles Turck, PharmD, BCPS, BCCCP
- Neeraj Agarwal, MD, FASCO
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Project Oncology®
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
- Rishi Sekar, MD
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Project Oncology®
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
- Zachery Reichert MD, PhD
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Global Oncology Academy
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
- Jacob Sands, MD
- Aakesh Desai, MD, MPH
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits

15/11